COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
LY-CoV555 and LY-CoV016 are two SARS-CoV-2 neutralizing antibodies which bind complementary regions of the SARS-CoV-2 spike protein. Studies are investigating their use in monotherapy and in combination. Submit updates/corrections below.
PrEP Lilly, Press Release (Preprint) symp. case, ↓57.0%, p=0.0002 Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Press release on the BLAZE-2 trial at nursing homes showing significantly lower symptomatic COVID-19 with treatment.
Early Gottlieb et al., JAMA, doi:10.1001/jama.2021.0202 (Peer Reviewed) hosp./ER, ↓70.6%, p=0.05 Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
RCT for LY-CoV555 monotherapy and LY-CoV555/LY-CoV016 combination therapy with 592 patients showing lower hospitalization/ER visits with treatment. For viral load at day 11, a statistically significant reduction was found with combinatio..
Late ACTIV-3/TICO LY-CoV555 study group, NEJM, doi:0.1056/NEJMoa2033130 (Peer Reviewed) death, ↑100%, p=0.22 A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Late stage RCT of LY-CoV555 added to remdesivir, showing non-statistically significant higher mortality with the addition of LY-CoV555.
Early Chen et al., NEJM, doi:10.1056/NEJMoa2029849 (Peer Reviewed) hosp., ↓74.3%, p=0.02 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Interim analysis of the BLAZE-1 phase 2 trial of outpatients showing lower hospitalization or ER visits (1.6% versus 6.3%), and improvements in symptoms and viral load compared to placebo. NCT04427501
News Lilly (News) news Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
ACTIV-3 intermin analysis shows LY-CoV555 is unlikely to help hospitalized patients. ACTIV-2, BLAZE-1 and BLAZE-2 trials remain ongoing.
Early Lilly (Preprint) hosp., ↓84.5%, p=0.05 SARS-CoV-2 neutralizing antibody program update
Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization. Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The ..
Please send us corrections, updates, or comments.